Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired



About Kerberos Proximal Solutions

Kerberos Proximal Solutions Inc., in Cupertino, Calif., developed proximal embolic-protection technology to recover debris dislodged during angioplasty and stent placement. The Kerberos device could lower significantly the embolic risk of these measures and make them more accessible to a broader patient population. The RCT BioVentures investment helped Kerberos perfect a mechanical model and demonstrate its use in animals. Kerberos received clearance from the U.S. Food and Drug Administration in September 2004 for coronary and peripheral use of the Rinspiration System. Rinspiration is focal simultaneous rinsing and aspiration administered by a single catheter. Later in the same month, Kerberos performed its 200th case of Rinspiration at New York Presbyterian/Columbia University Medical Center. The continued success of the Kerberos system in multi-device treatment interventions was one of the showcases highlighted at the IX Live Symposium of Complex Coronary and Cardiovascular Cases in New York in June 2006. In August 2006, FoxHollow Technologies ((Nasdaq: FOXH) announced a merger agreement to acquire Kerberos. Under the agreement, FoxHollow committed to pay about $32 million at closing, of which about $13 million it paid in stock.

Kerberos Proximal Solutions Headquarters Location

10600 North Tantau Avenue

Cupertino, California, 95014,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Kerberos Proximal Solutions News

St. Jude Medical's largest backer boosts stake by 30% | Wall Street Beat

May 8, 2012

MFS Investment Management, which invented the mutual fund, adds 7 million shares to its stake in St. Jude Medical, taking its share to 10% of the medical device maker; also, Smith & Nephew's Bioventus ortho-biologics JV fledges, Kalypto deal closes; Kerberos Proximal Solutions puts Rinspiration on the auction block; NeuroLogica helps develop 1st mobile stroke ambulance; Xtend Medical gets into the entertainment game; plus, a Funding Roundup and analysts' ups and downs.

  • When was Kerberos Proximal Solutions founded?

    Kerberos Proximal Solutions was founded in 2001.

  • Where is Kerberos Proximal Solutions's headquarters?

    Kerberos Proximal Solutions's headquarters is located at 10600 North Tantau Avenue, Cupertino.

  • What is Kerberos Proximal Solutions's latest funding round?

    Kerberos Proximal Solutions's latest funding round is Acquired.

  • Who are the investors of Kerberos Proximal Solutions?

    Investors of Kerberos Proximal Solutions include Foxhollow Technologies, Three Arch Partners and Alta Partners.

  • Who are Kerberos Proximal Solutions's competitors?

    Competitors of Kerberos Proximal Solutions include Endologix, Tryton Medical, Sonitus Medical, Corpora Systems, Small Bone Innovations, IDev Technologies, Flexible Stenting Solutions, Caliber Imaging & Diagnostics, VasoNova, Embrella Cardiovascular and 15 more.

You May Also Like

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Fox Hollow Technologies

Fox Hollow Technologies, Inc. has developed a coronary catheter that facilitates complete coronary lesion de-bulking, which has been shown to significantly reduce restenosis. The company's technology is designed to address the needs of the interventional cardiologist for a process that has traditionally been complex and has not allowed for complete de-bulking.

Micell Technologies

Micell Technologies aims to bring together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent.

TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.


SquareOne is developing a stent delivery system.

InterRad Medical

InterRad Medical is developing a catheter anchoring device called SecurAcath Catheter Retention System. The SecurAcath System is a new and method for holding catheters in place over and extended time. The SecurAcath System aims to utilize a very small anchor that deploys just under the skin to hold a catheter securely in place.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.